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Where have all the diabetics gone? 
W F Mollentze, J M M Koning
To the Editor: A recently published MRC Technical Report 
highlights the fact that the quality of diabetes care at all levels 
of public health care in South Africa is sub-optimal.1 This 
is probably also true for diabetes care in the Free State (FS) 
province. The reasons for poor quality of care include patient 
numbers, acute staff shortages, inadequate training of nurses, 
lack of necessary equipment and sufficient medication, poor 
patient compliance and ineffective patient education. 
An essential step in the planning of improved health care 
for diabetics in the FS is to establish the number of diabetic 
patients who are dependent on the public sector for their 
health care needs as well as the geographical distribution of 
patients and services. In the absence of a diabetes registry in 
the FS the number of diabetic patients in the province has to 
be estimated. Two approaches are possible, firstly to estimate 
the number of patients according to known prevalence rates of 
diabetes in the province, and secondly to calculate the number 
of patients according to the use of glucose-lowering medication 
provided by the provincial medicine depot during a specified 
period.
Estimated number of diabetics in the 
FS according to prevalence rates
The size of the FS population was 2.707 million in 2001; 
1 314 810 were aged 25 years or older.2 The age- and sex-
adjusted prevalences of diabetes and impaired glucose 
tolerance (IGT) in Bloemfontein in black subjects aged 25 years 
and older were 7.1% and 13.1% respectively.3 The calculated 
numbers of diabetics and subjects with IGT in the FS province 
were therefore approximately 93 352 and 172 240 respectively 
in 2005, provided that the population remained stable since 
2001. As elsewhere in the world, only half of all affected 
individuals are aware of the fact they have diabetes3 and the 
majority of patients with diabetes could be classified as having 
type 2 diabetes as this is the most prevalent type worldwide.4 
The total number of known patients with diabetes in the FS 
during the period June 2005 to May 2006 was therefore at least 
46 676, while a similar number of individuals were unaware of 
the fact that they had diabetes.  
Estimated number of diabetics in 
the FS according to annual usage of 
glucose-lowering medication
The FS provincial medicine depot provided on request the 
type, quantity and cost of glucose-lowering medication 
acquired during the period 1 June 2005 to 31 May 2006. 
According to the acquisition officer medicine is normally 
acquired on an on-going basis to maintain stock at the same 
level (J Meiring – personal communication). It is therefore safe 
to assume that the full amount of glucose-lowering medication 
acquired during this period was actually ordered by hospitals 
and clinics and eventually consumed by diabetic patients 
during a similar period. 
A total volume of 1 259 460 ml of insulin (125 946 000 units) 
was bought at a cost of R6.471 million. The average weight of 
a diabetic patient attending the diabetes clinic at Universitas 
Hospital was 84 kg (J M M Koning – presentation at 37th 
meeting of the Society for Endocrinology, Metabolism and 
Diabetes of South Africa, Sandton, 2001). The average dose of 
insulin used per patient per day was estimated to be 0.75 U/kg 
or 63 U. This means that approximately 5 477 patients were 
treated with insulin during a 12-month period. Because the 
number of patients younger than 25 years suffering from type 
1 diabetes is fairly small, these patients were not taken into 
consideration. 
During the same period 19 802 144 metformin tablets (500 
mg tablets) were acquired. If the average dose of metformin is 
estimated to be 4 - 6 tablets per patient per day, some 9 042 -  
13 563 patients (average  11 303 patients) consumed these 
tablets during a 1-year period at a total cost of R1.992 million.
Gliclazide in the form of 80 mg tablets was the most 
prescribed sulphonylurea, of which a total of 9 081 800 tablets 
were acquired during the 12-month period. At an average dose 
of 2 - 4 tablets per day some 6 220 to 12 440 patients (average 
9 331 patients) were treated during the 12-month period at a 
cost of R1.056 million. In addition, 2 624 328 glibenclamide 
tablets (5 mg) were also consumed during the same period. At 
an average dose of 3 tablets per patient per day, a further 2 397 
patients were treated with a sulphonylurea at an additional 
cost of R1.071 million. The total number of patients taking 
sulphonylureas during the 12-month period was therefore 
approximately 11 728 at a total cost of R2.127 million. 
Apart from the R10.59 million that was spent on glucose-
lowering medication, an additional R1.67 million was spent 
on blood glucose test strips, bringing the total amount spent 
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during a 1-year period in the FS on pharmaceuticals for 
diabetes care to R12.26 million (excluding the cost of disposable 
syringes). 
The practice of combining insulin and oral agents has not 
yet become fashionable within the public service in the FS. 
Combining sulphonylurea and metformin therapy, however, 
is common practice in this province as it is elsewhere in South 
Africa.5,6 Assuming that approximately 33% of patients treated 
with metformin also received a sulphonylurea, 7 573 patients 
received metformin only, 3 730 received metformin and a 
sulphonylurea, and 7 998 received only sulphonylureas (Fig. 1). 
The number of patients receiving glucose-lowering medication 
in the FS during 2005/6 therefore totalled 24 778. It is unlikely 
that more than 8% of patients were able to achieve satisfactory 
diabetes control by diet alone,7 accounting for approximately 
another 3 734 patients. 
Allowance also had to be made for patients cared for by 
the private sector. Approximately 6 million South Africans 
(13.4%) had medical aid cover during the preceding year.8 This 
means that approximately 6 255 of the total number of diabetic 
patients in the FS received private medical care during the 
study period. 
Discussion
According to these conservative estimates 11 909 or 25.5% 
of the ‘known’ diabetic patients could not be accounted for 
during the study period (Fig. 1). We acknowledge that the 
methods used to calculate patient numbers are not exact. 
Our main concern, however, is not the exact proportion of 
patients who cannot be accounted for, but the mere fact 
that such a sizeable group exists. Several possibilities exist 
to explain the ‘missing’ or unaccounted patients.  Firstly, a 
sizeable proportion of the ‘missing’ patients may simply be 
non-compliant. Secondly, some of the diagnosed patients may 
be relatively asymptomatic and therefore opt not to take the 
trouble of re-entering the cumbersome primary health care 
system once diagnosed. Finally, other barriers such as lack of 
transport and ill health due to advanced HIV/AIDS or other 
diseases may prevent patients from seeking help. Another 
possible confounding factor is the fact that a number of 
patients with medical aid insurance run out of benefits towards 
the end of the year and then temporarily enter the public 
health care service for assistance, only to migrate back to the 
private sector at the start of a new financial cycle. 
The main aim of this audit was to estimate patient numbers 
in the FS as a first step towards restructuring diabetes care 
in the province. It is now possible to plan diabetes services 
according to projected patient numbers per region. More 
importantly, it is now also possible to examine the capacity of 
the primary health care service at clinic and district level to 
provide proper diabetes care based on recognised national and 
international guidelines and according to estimated patient 
numbers. We trust that this audit will stimulate debate and 
contribute to an increased awareness of the shortcomings in 
diabetes care in both the public and private sectors in South 
Africa. There is a need not only to face the challenge of 
‘missing’ patients but also to initiate a screening programme to 
find and treat the undiagnosed ‘other half’.
We wish to thank Mr M S Shuping, then acting Head of Health, 
Free State, for permission to publish and Mr J Meiring, Provincial 
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Fig. 1. Estimated number of patients 25 years and older with diabetes in 
the FS in 2006 according to prevalence rates (N = 46 676) and treatment 
status based on 2001 census figure.
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